China NT Pharma Group Company Limited (HKG:1011)
0.4100
0.00 (0.00%)
Sep 30, 2026, 9:58 AM HKT
HKG:1011 Revenue
China NT Pharma Group Company had revenue of 23.67M CNY in the half year ending June 30, 2026, a decrease of -24.39%. This brings the company's revenue in the last twelve months to 35.83M, up 92.02% year-over-year. In the year 2025, China NT Pharma Group Company had annual revenue of 24.16M, down -36.36%.
Revenue (ttm)
35.83M CNY
Revenue Growth
+92.02%
P/S Ratio
9.41
Revenue / Employee
1.12M CNY
Employees
32
Market Cap
389.09M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.16M | -13.80M | -36.36% |
| Dec 31, 2024 | 37.96M | 30.59M | 415.34% |
| Dec 31, 2023 | 7.37M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 226.70M | 4.97M | 2.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 8.02B |
| Adicon Holdings | 3.06B |
| Kindstar Globalgene Technology | 1.10B |
| Yunkang Group | 624.49M |
| Mega Genomics | 413.73M |
| Biosino Bio-Technology and Science Incorporation | 196.98M |
| Zhong Ji Longevity Science Group | 150.07M |
| King International Investment | 143.23M |